The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein—a well-known, yet poorly understood drug transporter

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–917 Katzung BG (2007) Basic and Clinical Pharmacology. 10th edition, p 879. Andreoli TE, Bennet JC, Carpenter CCJ, Plum F (1997) Cecil Essentials of Medicine. 4th edition, p 425. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967–72 Amiri-Kordestani L, Basseville A, Kurdziel K, Fojo AT, Bates SE (2012) Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updat 15:50–61 Fudin J, Fontenelle DV, Fudin HR, Carlyn C, Hinden DA, Ashley CC (2013) Potential P-glycoprotein pharmacokinetic interaction of telaprevir with morphine or methadone. J Pain Palliat Care Pharmacother 27:261–7 Robey RW, Shukla S, Finley EM, Oldham RK, Barnett D, Ambudkar SV, Fojo T, Bates SE (2008) Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)- mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol 75:1302–12 Leitner I, Nemeth J, Feurstein T, Abrahim A, Matzneller P, Lagler H, Erker T, Langer O, Zeitlinger M (2011) The third-generation P-glycoprotein inhibitor tariquidar may overcome bacterial multidrug resistance by increasing intracellular drug concentration. J Antimicrob Chemother 66:834–9 Coley HM (2010) Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors. In Multi-Drug Resistance in Cancer, Humana Press, pp. 341–358. Holland IB, Cole SPC, Kuchler K, Higgens CF (2003) ABC proteins: from bacteria to man. Elsevier Science, London, 251 Brüggemann EP, Germann UA, Gottesman MM, Pastan I (1989) Two different regions of P-glycoprotein [corrected] are photoaffinity-labeled by azidopine. J Biol Chem 264:15483–8 Safa AR (2004) Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators. Curr Med Chem Anticancer Agents 4:1–17 Loo TW, Bartlett MC, Clarke DM (2003) Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein. Direct evidence for the substrate induced fit mechanism for drug binding. J Biol Chem 278:13603–6 Globisch C, Pajeva IK, Wiese M (2008) Identification of putative binding sites of P-glycoprotein based on its homology model. ChemMedChem 3:280–95 Maki N, Hafkemeyer P, Dey S (2003) Allosteric modulation of human P-glycoprotein. Inhibition of transport by preventing substrate translocation and dissociation. J Biol Chem 278:18132–9 Badhan R, Penny J (2006) In silico modelling of the interaction of flavonoids with human P-glycoprotein nucleotide-binding domain. Eur J Med Chem 41:285–95 Ambudkar SV, Kim IW, Xia D, Sauna ZE (2006) The A-loop, a novel conserved aromatic acid subdomain upstream of the Walker A motif in ABC transporters, is critical for ATP binding. FEBS Lett 580:1049–55 Mechetner EB, Roninson IB (1992) Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci U S A 89:5824–8 Georges E, Tsuruo T, Ling V (1993) Topology of P-glycoprotein as determined by epitope mapping of MRK-16 monoclonal antibody. J Biol Chem 268:1792–8 Nagy H, Goda K, Arceci R, Cianfriglia M, Mechetner E, Szabó G Jr (2001) P-Glycoprotein conformational changes detected by antibody competition. Eur J Biochem 268:2416–20 Regev R, Assaraf YG, Eytan GD (1999) Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug resistant cells. Eur J Biochem 259:18–24 Cai C, Zhu H, Chen J (2004) Overexpression of caveolin-1 increases plasma membrane fluidity and reduces P-glycoprotein function in Hs578T/Dox. Biochem Biophys Res Commun 320:868–74 Wang YH, Li Y, Yang SL, Yang L (2005) Classification of substrates and inhibitors of P-glycoprotein using unsupervised machine learning approach. J Chem Inf Model 45:750–7 Kim RB (2002) Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 34:47–54 Choi CH (2005) ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int 5:30 Bolton E, Wang Y, Thiessen PA, Bryant SH (2008) PubChem: integrated platform of small molecules and biological activities. Chapter 12 IN annual reports in computational chemistry, volume 4. American Chemical Society, Washington Sadowski J, Gasteiger J, Klebe G (1994) Comparison of automatic three-dimensional model builders using 639 X-Ray structures. J Chem Inf Comput Sci 34:1000–8 Tajima Y, Nakagawa H, Tamura A, Kadioglu O, Satake K, Mitani Y, Murase H, Regasini LO, da Silva Bolzani V, Ishikawa T, Fricker G, Efferth T (2013) Nitensidine A, a guanidine alkaloid from Pterogyne nitens, is a novel substrate for human ABC transporter ABCB1. Phytomedicine [Epub ahead of print] Zeino M, Zhao Q, Eichhorn T, Hermann J, Müller R, Efferth T (2013) Molecular docking studies of myxobacterial disorazoles and tubulysins to tubulin. J Biosci Med 3:31–43 Hartmann J (2000) Choosing the correct statistical test. University of Alabama, USA, http://bama.ua.edu/~jleeper/627/choosestat.html, last retrieved: 12.12.2013. Wise JG (2012) Catalytic transitions in the human MDR1 P-glycoprotein drug binding sites. Biochemistry 51:5125–41 Klepsch F, Chiba P, Ecker GF (2011) Exhaustive sampling of docking poses reveals binding hypotheses for propafenone type inhibitors of P-glycoprotein. PLoS Comput Biol 7:e1002036 Tang F, Ouyang H, Yang JZ, Borchardt RT (2004) Bidirectional transport of rhodamine 123 and Hoechst 33342, fluorescence probes of the binding sites on P-glycoprotein, across MDCKMDR1 cell monolayers. J Pharm Sci 93:1185–94 Loo TW, Clarke DM (2002) Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein. J Biol Chem 277:44332–8 Ferreira RJ, Ferreira MJ, dos Santos DJ (2013) Molecular docking characterizes substrate binding sites and efflux modulation mechanisms within P-glycoprotein. J Chem Inf Model 53:1747–60 Shapiro AB, Ling V (1997) Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 250:130–7 Loo TW, Clarke DM (2001) Defining the drug-binding site in the human multidrug resistance P-glycoprotein using a methanethiosulfonate analog of verapamil, MTS-verapamil. J Biol Chem 276:14972–9 Kothandan G, Gadhe CG, Madhavan T, Choi CH, Cho SJ (2011) Docking and 3D-QSAR (quantitative structure activity relationship) studies of flavones, the potent inhibitors of p-glycoprotein targeting the nucleotide binding domain. Eur J Med Chem 46:4078–88 Bansal T, Jaggi M, Khar RK, Talegaonkar S (2009) Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci 12:46–78 Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 30:2785–91